Cagrilintide 10mg (Amylin Analogue) – Lyophilized Peptide Vial

Cagrilintide 10mg – Advanced Amylin Analogue for Research

Cagrilintide 10mg is a cutting-edge, long-acting analogue of the naturally occurring hormone amylin. Engineered for superior metabolic stability, this 10mg lyophilized peptide is at the forefront of obesity and weight-management research in 2026. While traditional incretin mimetics target the GLP-1 receptor, Cagrilintide operates via a distinct mechanism—agonizing the amylin and calcitonin receptors to induce profound satiety and modulate gastric emptying.

In recent clinical evaluations, Cagrilintide has demonstrated a synergistic effect when paired with GLP-1 or GIP agonists, marking it as a “foundational” peptide for the next era of dual and triple-hormone therapy research.

Mechanism of Action: Satiety via the Amylin Pathway

Cagrilintide provides a multi-modal approach to appetite regulation that differs fundamentally from standard peptide therapies:

• Central Satiety Signaling: Acts directly on the brain’s area postrema to enhance the “fullness” signal, leading to a natural reduction in caloric intake.

• Delayed Gastric Emptying: Slows the rate at which food leaves the stomach, prolonging post-meal satisfaction and smoothing out postprandial glucose spikes.

• Glucagon Suppression: Helps regulate blood sugar by inhibiting inappropriate glucagon secretion during meals.

• Synergistic Compatibility: Research indicates that when combined with GLP-1 receptor agonists (such as Semaglutide), the dual-pathway approach can lead to significantly higher weight reduction than either compound alone.

Specifications and Research Quality

Our Cagrilintide 10mg is synthesized to exceed 99% purity, ensuring reliable data for clinical and laboratory settings.

• Active Sequence: Long-acting amylin analogue (Cagrilintide)

• Concentration: 10 mg per vial

• Form: Lyophilized powder for reconstitution

• Purity: Exceeds 99% (HPLC and MS Verified)

• Storage: Store at -20°C for long-term stability or 2°C–8°C for up to 3 months once reconstituted.

• Authenticity: Every vial features a unique batch-tracking code for verification of laboratory analysis.

Research Administration and Protocol

Cagrilintide 10mg is designed for once-weekly administration due to its extended half-life:

• Standard Research Dose: Typically starts at 0.3 mg to 0.6 mg per week, titrating upward based on the specific research protocol.

• Maximum Research Threshold: Protocols often reach a maintenance phase of 2.4 mg to 4.5 mg per week.

• Reconstitution: Best reconstituted with Bacteriostatic Water to ensure sterility and stability for multi-dose use.

• Injection Site: Subcutaneous injection in the abdominal fat, thigh, or upper arm.